aplastic anemia
Conditions
Interventions
Experimental group:IST (ATG+CsA)+ hetrombopag + umbilical cord blood
Control group:IST (ATG+CsA)+ hetrombopag
Sponsors
Tianjin Medical University General Hospital
Eligibility
Sex/Gender
All
Age
17 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age > 16 years; 2. Diagnosis of severe aplastic anemia and transfusion-dependent non-severe aplastic anemia; 3. Platelet count < 30 × 109/L; 4. No obvious organic diseases.
Exclusion criteria
Exclusion criteria: 1. Other conditions which investigator assessed not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The changes of platelet count, hemoglobin, white blood cell count, reticulocyte percentage and other indicators after 24 weeks of treatment.; | — |
Secondary
| Measure | Time frame |
|---|---|
| The changes of platelet count, hemoglobin, white blood cell count, reticulocyte percentage and other indicators after 12 weeks and 52 weeks of treatment.;Survival and progression-free survival after 12 and 52 weeks of treatment;The occurrence and severity of adverse reactions during treatment;The changes of bone marrow after 12 weeks and 52 weeks of treatment;Assessment of quality of life at 12 weeks and 52 weeks after treatment; | — |
Countries
China
Contacts
Public ContactFu Rong
Tianjin Medical University General Hospital
Outcome results
None listed